Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | PRNP | P04156 | 5/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | NCEH1 | Q6PIU2 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937151 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2HPGDPRNPRXFP1LMNA | |
| SCHEMBL29625686 | 0.83 | PRNP (0.50) | SMN1; SMN2HPGDPRNPRXFP1LMNA | |
| SCHEMBL23515145 | 0.83 | PRNP (0.50) | SMN1; SMN2HPGDPRNPRXFP1LMNA | |
| SCHEMBL26622001 | 0.82 | RAB9A (0.55) | SMN1; SMN2HPGDPRNPRXFP1LMNA | |
| SCHEMBL29820187 | 0.82 | MAPT (0.63) | SMN1; SMN2HPGDRAB9AMAPTALDH1A1 | |
| SCHEMBL1446528 | 0.82 | MAPT (0.63) | SMN1; SMN2HPGDRAB9AMAPTALDH1A1 | |
| SCHEMBL15287590 | 0.81 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDPRNPRXFP1LMNA | |
| SCHEMBL12745123 | 0.81 | MAPT (0.58) | SMN1; SMN2HPGDPRNPRXFP1LMNA | |
| SCHEMBL15285233 | 0.81 | MAPT (0.47) | SMN1; SMN2HPGDRAB9AMAPTNPC1 | |
| SCHEMBL8731312 | 0.81 | NCEH1 (0.47) | SMN1; SMN2HPGDRAB9AMAPK1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-3908283-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2020146613-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-1019046-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020049316-A1 | Protease inhibitors | HALBERT STACIE MARIE (US) | 2002-04-25 | — | — | US | disclosed |
| EP-1019046-A1 | PROTEASE INHIBITORS | Smithkline Beecham (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998048799-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049316-A1 | Protease inhibitors | CTSK, CTSZ, CTSG | SMN1; SMN2 4810/4885HPGD 392/4885PRNP 419/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | SMN1; SMN2 4385/4885HPGD 1741/4885PRNP 4718/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | SMN1; SMN2 4385/4885HPGD 1741/4885PRNP 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.